We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TJD5

News List

I-Mab, Kalbe Genexine Enter Strategic Pact contractpharma
April 01, 2020
KG Bio will have option for exclusive rights to commercialize two I-Mab product candidates.
I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5 En-CPhI.CN
October 08, 2019
I-Mab Biopharma , a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics ...
I-Mab Biopharma Receives FDA IND Clearance for Proprietary CD73 Antibody TJD5 americanpharmaceuticalreview
January 23, 2019
I-Mab Biopharma announced the Investigational New Drug (IND) application for the initiation of a Phase 1 clinical study for TJD5 in patients with advanced solid tumor has cleared the required 30 day review by the U.S. Food and Drug Administration (FDA)...